In a welcome move, Liquidia saw its Relative Strength Rating improve from 68 to 71 on Friday.
This proprietary rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks tend to have an RS Rating of over 80 in the early stages of their moves. See if Liquidia can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Liquidia has moved more than 5% past a 9.95 entry in a first-stage cup without handle, meaning it's now out of a proper buy range. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Liquidia posted 0% earnings growth in the latest quarterly report, while sales growth came in at 21%.
Liquidia earns the No. 259 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
